Hypertension, also known as high or raised blood pressure, is a global health issue with potential risk for long-term cardiovascular and renal complications.
WHAT IS HYPERTENSION?
Hypertension, also known as high or raised blood pressure, is a global health issue with potential risk for long-term cardiovascular and renal complications. (1) Patients rarely experience symptoms in the early stages of hypertension and many go undiagnosed. The majority of patients with hypertension are treated by primary care physicians.
Blood pressure is measured in millimetres of mercury (mmHg) and recorded as the upper number or systolic (highest pressure in blood vessels when the heart squeezes) over the lower number or diastolic (lowest blood pressure in blood vessels when the heart relaxes). As there can be large spontaneous variations in blood pressure, hypertension is diagnosed based on multiple systolic blood pressure readings above 140 mmHg or diastolic blood pressure readings above 90 mmHg taken on several separate occasions. (2) 
HOW RELEVANT IS THIS TO MY PRACTICE?
In Singapore, the 2010 National Health Survey showed a slight decrease in crude prevalence of hypertension, from 27.3% in 1998 to 24.9% in 2004 and 23.5% in 2010 (Table I) . (3) In 2014, the Joint National Committee (JNC) published the latest guideline for high blood pressure management, providing a summary of the current available evidencebased recommendations for our practising reference, in the absence of any local guidelines (the withdrawn Ministry of Health clinical practice guidelines for hypertension was dated 2005).
CLINICAL APPROACH TO HYPERTENSION
Differences in approach to the current available evidence between JNC 7 and JNC 8
The JNC 8 (4) approached the medical literature with a limited number of questions judged to be of the highest priority and restricted the initial systematic review to only randomised controlled trials (Table II) . The JNC 7, on the other hand, addressed multiple issues and reviewed a range of study designs. ABSTRACT Hypertension is the most common chronic condition seen in primary care. It is a potentially modifiable risk factor for cardiovascular and renal complications. The latest Joint National Committee recommendations in 2014 address common clinical questions from the best available science with regard to managing patients with hypertension. We review some of these recommendations and discuss how they may be applied in our practice.
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1. Hypertension is a global health issue with a potential risk for long-term cardiovascular and renal complications. 2. The majority of patients with high blood pressure experience symptoms in the early stages and seek treatment from their primary care doctors. 3. The majority of patients are unaware of their hypertension, as they do not experience any symptoms. 4. The systolic blood pressure (SBP) measures the pressure in the heart when it squeezes. 5. The diastolic blood pressure (DBP) measures the pressure in the blood vessels when the heart relaxes. randomised controlled trials, and hence, its recommendations may differ from those of previous JNC reports and other CPGs that included a range of study designs in their reviews. 10. For patients aged < 60 years, it is recommended to initiate pharmacologic treatment to reach a target SBP < 140 mmHg and DBP < 90 mmHg. 11. For patients aged ≥ 60 years, it is recommended to initiate pharmacologic treatment to reach a target SBP < 140 mmHg and DBP < 90 mmHg. 12. According to the JNC 8, it is recommended that patients aged ≥ 18 years with chronic kidney disease (CKD) be initiated on pharmacologic treatment to reach a target SBP < 140 mmHg and DBP < 90 mmHg. 13. According to the MOH CPG on Diabetes Mellitus 2014, patients with type 2 diabetes mellitus who have hypertension should be treated to reach a target SBP < 140 mmHg and DBP < 80 mmHg. 14. The MOH CPG on Diabetes Mellitus 2014 recommends that patients with type 2 diabetes mellitus and hypertensive patients with type 2 diabetes mellitus have the same target DBP (i.e. treatment to reach a target SBP < 140 mmHg and DBP < 80 mmHg). 15. An angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) should be included as part of the antihypertensive regimen for people with type 2 diabetes mellitus requiring pharmacotherapy for hypertension, unless it is not well tolerated. 16. For patients aged ≥ 18 years with CKD, initial (or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. 17. The recommended review period, should the patient fail to reach the target blood pressure, should be within a month of treatment. 18. If the target blood pressure cannot be attained with two drugs, a third drug should not be started without further investigations. 19. Do not use ACEI and ARB together in the same patient. 20. Referral to a specialist may be indicated for patients in whom the target blood pressure cannot be attained. 
